Articles

What happens when medications become easier to take—but harder to track? Oral and monthly GLP‑1 therapies promise fewer injections and less hassle, yet they may also create blind spots in patient care. As these long‑acting options reshape diabetes treatment, they’re also changing how clinicians must think about follow‑up, side effect …

Peripheral artery disease (PAD) affects millions of people with type 2 diabetes worldwide, increasing the risk of cardiovascular events and limb loss. With recent research into incretin‑based therapies, particularly glucagon‑like peptide‑1 receptor agonists (GLP‑1s), clinicians are asking whether these drugs can improve outcomes in PAD patients treated with GLP‑1s, beyond …

What if the key to resolving both diabetes and liver disease lies in a single therapeutic approach? As rates of metabolic dysfunction-associated steatohepatitis (MASH) rise among people with type 2 diabetes, many clinicians are rethinking how they prioritize treatment. Rather than treating glucose and liver health in silos, combining therapies …

Artificial intelligence (AI) is transforming many aspects of diabetes care, and smart insulin management powered by AI is quickly becoming one of its most promising innovations. Tools that read continuous glucose monitor (CGM) data and suggest insulin changes are rapidly entering clinical use. But while these tools are powerful, they …

Menopause marks a major transition in a woman’s life, defined not only by the end of menstrual cycles but also by profound hormonal and metabolic changes. One often under‑recognized shift is the acceleration of cardiometabolic risk. Women in midlife frequently experience increased central adiposity, changes in glucose regulation, rising blood …

For decades, metformin has been the backbone of type 2 diabetes therapy. As we move through 2026, the future of metformin in type 2 diabetes treatment is under fresh scrutiny. Should it still be the first-line agent, or have newer drug classes like GLP‑1 receptor agonists and SGLT2 inhibitors earned …

Glucagon‑like peptide‑1 receptor agonists (GLP‑1 RAs) have transformed type 2 diabetes management by improving blood sugar control and promoting weight loss. Yet as clinical use grows, so does interest in how GLP‑1 medications affect skeletal health — particularly their impact on bone density, remodeling, and fracture risk. This article unpacks …

Asthma is a chronic inflammatory disease of the airways that affects millions worldwide and often overlaps with metabolic conditions such as obesity and type 2 diabetes. Recently, interest has grown in whether glucagon‑like peptide‑1 receptor agonists (GLP‑1 RAs)—a class of drugs commonly used to manage diabetes and obesity—could help reduce …

Nonalcoholic steatohepatitis (NASH) and metabolic dysfunction–associated steatotic liver disease (MASLD) are rapidly becoming leading causes of chronic liver disease worldwide. Traditionally, clinicians have associated MASLD with obesity, insulin resistance, and type 2 diabetes, often using body mass index (BMI) and A1C as screening triggers. However, an important shift is occurring …

The updated ADA 2026 standards represent a major shift in how clinicians approach diabetes management. Rather than focusing solely on lowering A1C, these new recommendations promote a broader, holistic strategy that integrates cardiovascular, kidney, and metabolic (CKM) risk management into everyday care. This article breaks down the key updates and …